Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Janus Henderson Group plc files Amendment No. 2 to a Schedule 13G/A reporting ownership of 9,090,732 shares of Immix Biopharma, Inc. The filing states the Asset Managers controlled by Janus Henderson exercise shared voting and dispositive power over those shares, representing 13.0% of the class as disclosed. The filing notes that most Managed Portfolios hold the shares for clients and that only the Janus Henderson Biotech Innovation Master Fund Ltd. holds more than 5% of the class.
The filing is signed by a compliance officer on 06/05/2026 and references exhibits including a Power of Attorney and Item 7 details.
Immix Biopharma, Inc. reported the final voting results from its 2026 Annual Meeting of stockholders held on May 22, 2026. Stockholders elected all listed director nominees, including Ilya Rachman, Gabriel Morris and others, with each receiving over 34 million votes in favor and relatively few votes withheld.
Each director election also recorded 6,445,683 or 6,445,684 broker non-votes. A second proposal was approved with 42,276,496 votes for, 11,526 against and 18,442 abstentions, indicating strong support from voting shareholders for the matters presented.
Immix Biopharma director Helen C. Adams received new equity awards as part of her compensation. She was granted 6,250 restricted stock units of common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual shareholder meeting, subject to her continued service.
Adams was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036. These options vest in substantially equal monthly installments over 12 months following the grant date, or sooner if the 2027 annual meeting occurs earlier. After the RSU grant, her direct common stock holdings total 181,004 shares.
Immix Biopharma director Carey Ng reported new equity awards and updated holdings. He received 6,250 restricted stock units under the 2021 Equity Incentive Plan, which vest in full on the earlier of the one-year anniversary of grant or the 2027 annual stockholders’ meeting, subject to continued service. He was also granted a stock option for 12,500 shares of common stock at an exercise price of $8.78 per share, vesting in substantially equal monthly installments over 12 months or, if earlier, on the date of the 2027 annual meeting, with an expiration date in 2036. Following these awards, he directly holds 26,250 common shares and has indirect ownership of 1,025,221 shares through Mesa Verde Venture Partners III, LP, where he has voting and disposition power but disclaims beneficial ownership except for his pecuniary interest. The filing does not show any open-market purchases or sales.
Immix Biopharma director Magda Marquet reported new equity awards in the form of restricted stock units and stock options. On May 22, 2026, she was granted 6,250 restricted stock units under the company’s 2021 Equity Incentive Plan and 12,500 stock options with an exercise price of $8.78 per share.
The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of Immix Biopharma’s 2027 annual stockholder meeting, subject to continued service. The stock options vest in substantially equal monthly installments over 12 months, or fully on the 2027 annual meeting date if it occurs earlier, also subject to her continued board service.
Following these awards, Marquet directly holds 52,342 shares of common stock and 12,500 stock options, and is associated with 20,000 additional shares held indirectly by Alma Life Sciences, LLC, for which she disclaims beneficial ownership beyond any pecuniary interest.
Immix Biopharma, Inc. reported that its CFO and President, Morris Gabriel S, received a grant of stock options covering 500,000 shares of Common Stock. The options have an exercise price of $8.78 per share and expire on May 22, 2036. The award vests in 48 equal monthly installments after the grant date, tying the executive’s potential ownership to continued service with the company.
Immix Biopharma director Nancy T. Chang reported new equity awards, not open‑market trades. She received 6,250 restricted stock units under the 2021 Equity Incentive Plan, which vest in full on the earlier of the one-year anniversary of grant or the company’s 2027 annual stockholders’ meeting, subject to continued service.
She was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036, vesting in substantially equal monthly installments over 12 months or, if earlier, on the 2027 annual meeting date. After these awards, she holds 428,190 common shares directly and 496,940 shares indirectly through Robinhood II, LP, where she is general manager and disclaims beneficial ownership except for her pecuniary interest.
Immix Biopharma, Inc. reported that CEO and Chairman Ilya M. Rachman received a grant of stock options covering 500,000 shares of common stock. The options have an exercise price of $8.78 per share and expire on May 22, 2036.
These options were granted as compensation and do not represent an open-market purchase or sale. According to the terms, they vest in 48 equal monthly installments following the grant date, contingent on Dr. Rachman’s continued service with the company.
Immix Biopharma director Yekaterina Chudnovsky reported equity awards and updated holdings. She received 6,250 restricted stock units under the 2021 Equity Incentive Plan, vesting in full on the earlier of one year from grant or the 2027 annual stockholders meeting, subject to continued service.
She was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, vesting in substantially equal monthly installments over 12 months or, if earlier, on the date of the 2027 annual meeting, contingent on continued board service. Following this Form 4, she holds 6,250 common shares directly and 12,500 options, and is associated with 3,241,076 shares held indirectly by GKCC, LLC, where she is the sole member and manager.
Hsu Jason reported acquisition or exercise transactions in this Form 4 filing.
Immix Biopharma, Inc. director Jason Hsu reported new equity compensation. He received 6,250 restricted stock units that vest in full on the earlier of one year from grant or the company’s 2027 annual meeting, subject to continued service. He was also granted a stock option for 12,500 shares at $8.78 per share, vesting in equal monthly installments over 12 months or, if earlier, on the 2027 annual meeting date. After these awards, he holds 899,250 common shares directly, plus additional indirect holdings through VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC, where he has voting and disposition rights but disclaims beneficial ownership except for his pecuniary interest.